NeoGenomics Inc (NEO) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

Full Year Revenue Increased 12% to $661 million; Ninth Consecutive Quarter of Double-Digit Revenue Growth NeoGenomics, Inc. (Nasdaq: NEO) (the...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

PacBio Announces Appointment of Chris Smith to Board of Directors

MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of...

NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities